Are Circulating Tumor DNA and Urinary Tumor DNA the New PSA for Clinically Localized Muscle-Invasive Bladder Cancer in the Enfortumab Vedotin/Pembrolizumab Era?
Journal of Urology | April 29, 2026 | Volume: 216 | Issue: 3 | Pages: 324-326
10.1097/ju.0000000000005074